A case if invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid

Scandinavian Journal of Infectious Diseases

Volumn 39, Issue 4, 2007, Pages 344-346

  Okugawa, Shu ^a   Ota, Yasuo ^a   Tatsuno, Keita ^a   Tsukada, Kunihisa ^a   Kishino, Satoshi ^b   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; MICAFUNGIN; VORICONAZOLE;

AGED; ARTICLE; ASPERGILLOSIS; BRAIN BIOPSY; BRAIN SURGERY; CASE REPORT; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID EXAMINATION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG MEGADOSE; DRUG PENETRATION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT DISEASE; SEROLOGY; SYSTEMIC MYCOSIS;

AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; FEMALE; HUMANS; LIPOPROTEINS; NEUROASPERGILLOSIS; PEPTIDES, CYCLIC; RECURRENCE;

EID: 34147141461     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540600951333     Document Type: Article

References (11)

1. Clark, TA and Hajjeh, RA (2002) Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis, 15, pp. 569-574.
2. Kim, DG, Hong, SC, Kim, HJ, Chi, JG, Han, MH and Choi, KS (1993) Cerebral aspergillosis in immunologically competent patients. Surg Neurol, 40, pp. 326-331.
3. Colombo, AL and Rosas, RC (2003) Successful treatment of an Aspergillus brain abscess with caspofungin: Case report of a diabetic patient intolerant of amphotericin B. Eur J Clin Microbiol Infect Dis, 22, pp. 575-576.
4. Higashiyama, Y. and Kohno, S. (2004) Micafungin: A therapeutic review. Expert Rev Anti Infect Ther, 2, pp. 345-355.
5. Denning, DW (2003) Echinocandin antifungal drugs. Lancet, 362, pp. 1142-1151.
6. Chandrasekar, PH and Sobel, JD (2006) Micafungin: A new echinocandin. Clin Infect Dis, 42, pp. 1171-1178.
7. Groll, AH, Mickiene, D., Petraitis, V., Petraitiene, R., Ibrahim, KH and Piscitelli, SC (2001) Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother, 45, pp. 3322-3327.
8. Clemons, KV, Espiritu, M., Parmar, R. and Stevens, DA (2005) Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother, 49, pp. 4867-4875.
9. Kishino, S., Ohno, K., Shimamura, T., Furukawa, H. and Todo, S. (2004) Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant, 18, pp. 676-680.
10. Guinea, J., Pelaez, T., Alcala, L., Ruiz-Serrano, MJ and Bouza, E. (2005) Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: Analysis by site of isolation. Antimicrob Agents Chemother, 49, pp. 3495-3497.
11. Nakai, T., Uno, J., Otomo, K., Ikeda, F., Tawara, S. and Goto, T. (2002) In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important moulds. Chemotherapy, 48, pp. 78-81.